S. Cherry

Evolutionary arms race between SARS-CoV-2 and interferon signaling via dynamic interaction with autophagy.

This study identifies how SARS-CoV-2 evolves to counteract host interferon signaling through interactions with autophagy pathways.

Maternal immunization with distinct influenza vaccine platforms elicits unique antibody profiles that impact the protection of offspring

This study compares antibody profiles from maternal influenza vaccines in mice, showing LAIV and rHA provide better offspring protection than TIV.

Single cell susceptibility to SARS-CoV-2 infection is driven by variable cell states

This study identifies cell state variability as a key determinant of SARS-CoV-2 susceptibility by analyzing highly susceptible lung epithelial cells.

Improved metabolic syndrome and timing of weight loss is crucial for influenza vaccine-induced immunity in obese mice

This study shows pre-vaccination weight loss improves influenza vaccine efficacy in obese mice, while post-vaccination weight loss does not.

Leishmania amazonensis sabotages host cell SUMOylation for intracellular survival

This study identifies SUMOylation inhibition as a mechanism by which Leishmania amazonensis enhances its survival in host macrophages.

Multiplexed detection of SARS-CoV-2 genomic and subgenomic RNA using in situ hybridization

This paper develops an RNA FISH HCR platform to visualize SARS-CoV-2 genomic and subgenomic RNA in autopsy tissues and identifies infected cell types in human lung tissue.

Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection

The paper screens 18,000 drugs for antiviral activity against SARS-CoV-2, identifies synergistic combinations of pyrimidine biosynthesis inhibitors and nucleoside analogs, and validates their efficacy in vitro and in vivo.

Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents

The paper validates in vitro human lung tissue models for studying SARS-CoV-2 and influenza virus infections and antiviral treatments.

High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.

The paper screens drug libraries to find inhibitors of SARS-CoV-2 nsp15 endoribonuclease, identifying Exebryl-1 as a potential antiviral compound.

An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity

This study designs non-covalent SARS-CoV-2 Mpro inhibitors using structure-based design and Ugi-4CR reactions, identifying 23R as the most potent compound with antiviral activity.

Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2

The paper screens FDA-approved drugs against SARS-CoV-2 in different cell types, identifying three FDA-approved antivirals with potential for clinical use.

HA stability regulates H1N1 influenza virus replication and pathogenicity in mice by modulating type I interferon responses in dendritic cells

This paper shows that a destabilizing HA mutation in H1N1 influenza virus reduces replication and pathogenicity in mice by enhancing type I interferon responses in dendritic cells.